CHOP-B                                               lymphoma(87)
 _________________________________________________________________
  cytoxan......... 750 mg/sqm IV day 1.
  adriamycin...... 50 mg/sqm IV day 1.
  vincristine..... 2 mg IV on days 1 and 5.
  prednisone...... 100 mg/day orally from day 1 to day 5.
  bleomycin....... 15 U IV on days 1 and 5.
  FREQUENCY....... Repeat cycle every 21 or 28 days.

  reference...
    Rodriguez V.  Cabanillas F.  Burgess MA.  McKelvey EM.  
    Valdivieso M.  Bodey GP.  Freireich EJ. Combination 
    chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant 
    lymphoma. Blood.  49(3):325-33, 1977 Mar. 
  abstract...
    Forty-seven adults with advanced malignant lymphoma (the 
    majority in stage IV) were treated with a combination of 
    cyclophosphamide, hydroxyldaunorubicin (Adriamycin), 
    vincristine (Oncovin), prednisone, and bleomycin (CHOP-Bleo). 
    The complete remission (CR) rate was 66%. The overall response 
    (complete + partial remission) was 92%. The CR rate in 
    patients with diffuse histiocytic lymphoma (DHL) was 69%. Only 
    3 of the 18 patients with DHL in CR have relapsed; the 
    projected median duration of response was calculated to be 
    greater than 2 yr. In patients with nodular poorly 
    differentiated lymphocytic lymphoma (NPDL), the CR rate was 
    62%. One of the eight patients with NPDL in CR has relapsed; 
    the projected median duration of complete response will be 
    greater than 4 yr. The median survival for all patients 
    entered in this study has not been reached; however, it was 
    estimated that it will be greater than 3 yr. The survival 
    curves became flat at 70 wk for the patients with DHL and at 1 
    yr for the patients with NPDL. Major complications during 
    chemotherapy with CHOP-Bleo were myelosuppression and 
    alopecia. Only six severe infections occurred during 
    myelosuppression. No hemorrhagic problems were observed. This 
    study indicates that combination chemotherapy with these 
    agents is effective in increasing the CR rate and survival in 
    patients with diffuse histiocytic lymphoma. In patients with 
    NPDL, further observation will be needed to assess the effect 
    of this combination on survival.